Clin Pharmacol Ther. 2014 Aug;96(2):162-5. doi: 10.1038/clpt.2014.113. Epub 2014 May 22.

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.

Hutchison C¹, Kwong A², Ray S³, Struble K⁴, Swan T⁵, Miller V⁶.

Author information

1: School of Public Health, University of California-Berkeley, Berkeley, California, USA.
2: InnovaTID, Cambridge, Massachusetts, USA.
3: Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
4: Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
5: Treatment Action Group, New York, New York, USA.
6: Forum for Collaborative HIV Research, University of California-Berkeley, Washington, DC, USA.

Abstract

Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's(1) HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.